← Back to Patent Explorer
US5422364A Expired / Lapsed US ⏱️ 0.0 years remaining

Water soluble taxol derivatives

Assignee: Scripps Research Institute
•
Filing: 1993-09-16
•
Granted: 1995-06-06
•
Expires: 2013-09-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Alkaline sensitive protaxol is water soluble and is hydrolyzed at physiological (alkaline) pH to render the native taxol structure and the native taxol activity. Protaxol compositions include 2'- and/or 7-O-ester derivatives of taxol and/or 2'- and/or 7-O-carbonate derivatives taxol. Protaxol has a formula as follows: <IMAGE> wherein R1 and R2 are each H or a radical selected from the group consisting of -CO-(CH2)m-X-(CH2)n-COZ and -COO-(CH2)o-Y-Ar, and wherein m, n, and o are each an integer of 1 to 3; X is O, S, NH, SO, or SO2; Y is S, SO or SO2; Ar is phenyl or substituted phenyl wherein the substituent is halo, amino, nitro or N,N-dialkylamino having 1 to 4 carbons in each of the alkyl groups; and Z is OH, OR3, SR3 or NR4R5 wherein R3 is alkyl containing 1 to 4 carbons and R4 and R5 are each alkyl containing 1 to 4 carbons, or taken together with the nitrogen to which they are attached form a saturated heterocyclic ring having 4 or 5 carbons, with the proviso that at least on R1 and R2 is not hydrogen; as well as the salts of such compounds with organic/inorganic bases and acids, preferably pharmaceutically acceptable salts.

Inventors

  • 👤 K. C. Nicolaou
  • 👤 Claus G. Riemer
  • 👤 Michael A. Kerr

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 18:54
CPC Classifications
C; C07; C07D; C07D305/00; C07D305/14

Claims Analysis

Total Claims: 14
Claim 1
Independent Claim 122 words
A compound of the formula: ##STR21## wherein R 1 and R 2 are each H or a radical selected from the group consisting of --CO--(CH 2 ) m --X--(CH 2 ) n --COZ and --COO--(CH 2 ) o --Y--Ar, wherein m, n, and o are each an integer of 1 to 3; X is O, S, NH, SO, or SO 2 ; Y is S, SO or SO 2 ; Ar is phenyl or substituted phenyl wherein the substituent is halo, amino, nitro, or N,N-diallkylamino having 1 to 4 carbons in each of the alkyl groups; and Z is OH; with the proviso that at least one of R 1 and R 2 is not hydrogen, or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim 122 words
A compound of the formula: ##STR21## wherein R 1 and R 2 are each H or a radical selected from the group consisting of --CO--(CH 2 ) m --X--(CH 2 ) n --COZ and --COO--(CH 2 ) o --Y--Ar, wherein m, n, and o are each an integer of 1 to 3; X is O, S, NH, SO, or SO 2 ; Y is S, SO or SO 2 ; Ar is phenyl or substituted phenyl wherein the substituent is halo, amino, nitro, or N,N-diallkylamino having 1 to 4 carbons in each of the alkyl groups; and Z is OH; with the proviso that at least one of R 1 and R 2 is not hydrogen, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim 11 words
The compound according to claim 1, wherein R 2 is H.
Claim 4
Dependent Claim 19 words
The compound according to claim 2, wherein R 1 is --CO--(CH 2 ) m --X--(CH 2 ) n --COZ.
Claim 5
Dependent Claim 14 words
The compound according to claim 3, wherein each of m and n is 1.
Claim 6
Dependent Claim 10 words
The compound according to claim 3, wherein X is S.
Claim 7
Dependent Claim 15 words
The compound according to claim 2, wherein R 1 is --COO--(CH 2 ) o --Y--Ar.
Claim 8
Dependent Claim 10 words
The compound according to claim 6, wherein o is 2.
Claim 9
Dependent Claim 10 words
The compound according to claim 7, wherein Ar is phenyl.
Claim 10
Dependent Claim 24 words
The compound according to claim 1, wherein each of R 1 and R 2 is --CO--(CH 2 ) m --X--(CH 2 ) n --COZ.
Claim 11
Dependent Claim 14 words
The compound according to claim 9, wherein each of m and n is 1.
Claim 12
Dependent Claim 10 words
The compound according to claim 10, wherein X is S.
Claim 13
Dependent Claim 24 words
A pharmaceutical composition comprising a tumor inhibiting effective amount of the compound according to claim 1, together with a pharmaceutically acceptable carrier or diluent.
Claim 14
Dependent Claim 26 words
A method for inhibiting tumors in a mammal which comprises administering to the mammal a tumor inhibiting effective amount of the compound according to claim 1.

References Cited (Backward Citations)

US4942184A Cited
US4960790A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1998-06-05 1998-12-05 1999-06-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2002-06-05 2002-12-05 2003-06-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2006-06-05 2006-12-05 2007-06-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag